COMMUNIQUÉS West-GlobeNewswire

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder
24/09/2026
Exploratory research results presented at Psych Congress 2026 in New Orleans Full poster presentation can be found on “Publications” section of Company’s website SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE [...]
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
24/09/2026
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell [...]
PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment
24/09/2026
SHIELD Phase 2 Study: first payment made under the clinical trial agreement with Mount Sinai and study drug ordered; the randomized, double-blind, placebo-controlled study, registered as NCT07597902, plans to enroll [...]
Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product
24/09/2026
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the [...]
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
24/09/2026
Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel’s differentiated construct Sustained clinical [...]
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
24/09/2026
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
24/09/2026
Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activities in the fourth [...]
Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
24/09/2026
Biodesix-led tumor-informed and tumor-naïve programs draw on the company’s bioinformatics and diagnostics test development expertise LOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a [...]
Adventure With a Purpose: A Race Against Blindness Unveils Adventure Package Fundraiser Valued at $350,000
24/09/2026
One winner will receive a luxury Entegra Super C motorhome, Polaris XPEDITION, trailer, and $100,000 cash GILBERT, Ariz., Sept. 24, 2026 (GLOBE NEWSWIRE) -- A Race Against Blindness has launched one of the largest [...]
Coloplast A/S - Financial Calendar 2026/27
24/09/2026
Please see enclosed pdf. For more information and calendar invitations for upcoming events, please visit: https://investor.coloplast.com/investor-relations/financial-calendar-and-events/ Kind regards, Investor Relations [...]
Kasvu Therapeutics Raises €30 Million Series A Financing Round led by Hadean Ventures to Advance its Novel TrkB Potentiator into Clinical Development Targeting Neuropsychiatric Disorders
24/09/2026
Differentiated approach directly and selectively enhances TrkB activity, a central regulator of neuroplasticity New funds will advance lead programme KTX-0141 through IND/CTA-enabling studies and Phase 1/1b clinical [...]
Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer
24/09/2026
More than half of the patients planned for the clinical study have already been enrolled, with the trial progressing rapidly through dose escalation Advancement of ONA-255 marks an important milestone following Ona's $ [...]
BOOST Pharma Selected to Showcase Phase III Ready Lead Program BT-101 at the 2026 Cell & Gene Meeting on the Mesa
24/09/2026
BOOST Pharma (“BOOST” or “the Company”), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal diseases, today announced that [...]
Reminder: Register Now | Unlocking the Growth - BioPorto Investor Meeting, October 7
24/09/2026
September 24, 2026 News release Reminder: Register Now | Unlocking the Growth - BioPorto Investor Meeting, October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical [...]
Flen Health Chooses AGC Biologics to Manufacture Recombinant Enzymes for Next-Generation Wound Treatment
24/09/2026
Heidelberg site to lead GMP development of lactoperoxidase and glucose oxidase for Phase II clinical trials HEIDELBERG, Germany, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Belgian biopharmaceutical company Flen Health has [...]
Final Phase 2a data reinforce the profile of BIOX-101, selected for a late-breaking oral presentation at the World Stroke Congress
24/09/2026
Final Phase 2a data from the BIRCH trial of BIOX-101 in acute intracerebral hemorrhage, selected for a Late-Breaking Science oral presentation New data show statistically significant improvements across multiple [...]
Carbios reports first-half 2026 results
24/09/2026
19 % reduction in operating expenses compared with the first half of 2025, reflecting the financial discipline of the Group Solid cash position of €48 million as of June 30, 2026, enabling Carbios to cover its operating [...]
Carbios présente ses résultats semestriels 2026
24/09/2026
Réduction des dépenses opérationnelles de 19 % par rapport au 1 er semestre 2025, reflétant la discipline financière du Groupe Solide position de trésorerie de 48 millions d’euros au 30 juin 2026, permettant à Carbios [...]
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
24/09/2026
Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for [...]

Pages